Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPEP1 | P16444 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13299447 | 0.87 | MEN1 (0.55) | MEN1KMT2ALMNAMAPTNPSR1 | |
| SCHEMBL14533258 | 0.83 | DPEP1 (0.46) | DPEP1LMNAPARP10PARP15NFE2L2 | |
| SCHEMBL4008900 | 0.81 | LMNA (0.48) | MEN1KMT2ALMNAMAPTNPSR1 | |
| SCHEMBL13240377 | 0.80 | CDK2 (0.46) | — | |
| SCHEMBL4007127 | 0.78 | DPEP1 (0.39) | DPEP1MEN1KMT2ALMNAMAPT | |
| SCHEMBL5710011 | 0.75 | LMNA (0.53) | MEN1KMT2ALMNAMAPTNPSR1 | |
| SCHEMBL6924253 | 0.74 | MEN1 (0.72) | MEN1KMT2ALMNAMAPTNPSR1 | |
| SCHEMBL8472995 | 0.72 | KMT2A (0.54) | MEN1KMT2ALMNAMAPTNPSR1 | |
| SCHEMBL2155002 | 0.71 | MEN1 (0.49) | MEN1KMT2ALMNAMAPTNPSR1 | |
| SCHEMBL4004260 | 0.71 | MEN1 (0.49) | MEN1KMT2ALMNAMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100183530-A1 | Cosmetic compositions comprising 4-carboxy-2-pyrrolidinone esters and triazine lipophilic UV-screening agents | L'OREAL (FR) | 2010-07-22 | — | — | US | disclosed |
| EP-2193784-A1 | Cosmetic compositions containing an ester derivative of 2-pyrrolidinone 4-carboxy and a lipophilic triazine filter, with use of said derivative as a solvent of a lipophilic triazine filter | L'OREAL (FR) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009074409-A1 | S-TRIAZINE COMPOUNDS CONTAINING ONE AMINOSILOXANE GROUP AND TWO PARTICULAR PARA-AMINOBENZALMALONATE GROUPS; COSMETIC COMPOSITIONS CONTAINING SAID DERIVATIVES; USES OF SAID S-TRIAZINE DERIVATIVES | L'OREAL (FR) | 2009-06-18 | — | — | WO | disclosed |
| US-7217821-B2 | Photoprotective cosmetic compositions comprising para-aminobenzalmalonate-substituted s-triazine compounds | L'OREAL (FR) | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183530-A1 | Cosmetic compositions comprising 4-carboxy-2-pyrrolidinone esters and triazine lipophilic UV-screening agents | TYR, PAH, C1S | DPEP1 1948/4885MEN1 1842/4885KMT2A 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.